Tata Laksana Terintegrasi Sindrom Stevens-Johnson (SJS) dan Nekrolisis Epidermal Toksik (NET)
DOI:
https://doi.org/10.55175/cdk.v50i10.760Keywords:
Stevens-Johnson syndrome, toxic epidermal necrolysis, SJS-TENAbstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute life-threatening mucocutaneous reactions characterized by extensive epidermal necrosis and epidermal detachment. The incidence of SJS in Japan is 2.3 cases/100,000 people/per year. The mortality rate of SJS-TEN in Saudi Arabia is 1 per 10 cases (10%). SJS-TEN can be caused by drugs, idiopathic, infection, post-bone marrow transplant, immunization, radiotherapy, and genetics. The pathogenesis of SJS-TEN is suspected as a result of a cytotoxic reaction to keratinocyte cells which causes massive apoptosis. Clinical manifestation begins with prodromal symptoms followed by erythematous macular lesions and atypical target lesions that may confluence, then develop into bullous, oozing erosions with mucosal involvement. Vital sign observation is important to predict prognosis. A diagnostic procedure is necessary if another diagnosis is being considered. Management of SJS-TEN includes cessation of suspected drugs, early treatment such as fluid resuscitation, early nutrition, treatment and evaluation of eyes and skin lesions. Multiorgan involvement can occur in SJS-TEN so multidisciplinary management is needed for optimal therapy. Corticosteroids and cyclosporin A provide beneficial effects on SJS-TEN. SCORTEN is used to evaluate prognosis.
Downloads
References
Djuanda A, Suriadiredja ASD, Sudharmono A, Wiryadi BE, Kurniati DD. Ilmu penyakit kulit dan kelamin. In: Menaldi SLS, Bramono K, Indriatmi W, eds. 7th Ed. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2016.
Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al. Fitzpatrick’s dermatology. 9th ed. New York: McGraw-Hill Education; 2019.
James WD, Elston D, Treat J, Rosenbach M, Neuhaus I. Andrews’ diseases of the skin clinical dermatology. 13th ed. Philadelphia: Elsevier; 2020.
Ubukata N, Nakatani E, Hashizume H, Sasaki H, Miyachi Y. Risk factors and drugs that trigger the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis: A population-based cohort study using the Shizuoka Kokuho database. J Am Acad Dermatol. 2022;11:24–31.
Alajaji A, Shekaran JC, Aldhabbah OM, Alhindi HA, Almazyad NS, Aljutayli ZA, et al. Toxic epidermal necrolysis (TEN)/Stevens-Johnson syndrome (SJS) epidemiology and mortality rate at King Fahad Specialist Hospital (KFSH) in Qassim region of Saudi Arabia: A retrospective study. Dermatol Res Pr. 2020;2020:1–3.
Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, et al. Incidence of stevens-johnson syndrome and toxic epidermal necrolysis: A nationwide population-based study using national health insurance database in Korea. PLoS One. 2016;11(11):1–12.
Sunagaa Y, Michiko K, Hirotaka O, Hideaki W, Hirohiko S, Hiroaki A, et al. The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018. J Dermatol Sci. 2020;100(3):175–82.
Khosama H, Budikayanti A, Khor AHP, Lim KS, Ng CC, Mansyur IG, et al. HLA-B*1502 and carbamazepine induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Indonesia. Neurol Asia 2017;22(2):113–6.
Oki S, Yuwita W, Dharmadji, Hartati Purbo Sutedja E. Stevens-Johnson syndrome and toxic epidermal necrolysis in Dr. Hasan Sadikin General Hospital Bandung, Indonesia from 2009-2013. Asia Pac Allergy. 2016;6(1):43–7.
Isaac WA, Damayanti, Fatimah N, Hidayati AN. The profiles of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) patients in tertiary hospital. Berk Ilmu Kes Kulit Kelamin (Period Dermatol Venerol). 2021;33(2):116–22.
Chan F, Benson MD, Plemel DJA, Mahmood MN, Chan SM. A diagnosis of Stevens-Johnson syndrome (SJS) in a patient presenting with superficial keratitis. Am J Ophthalmol. 2018;19(11):167–9.
Łabno ES, Gabzdyl N, Misiak-Galazka M, Pawłowska-Kisiel M, Łazowski T, Rudnicka L. Stevens–Johnson syndrome and toxic epidermal necrolysis in an academic hospital setting: a 5-year retrospective study. Our Dermatol Online. 2016;7(4):381–4.
Lim JH, Cho SH, Lee JD, Kim HS. A case of Stevens-Johnson syndrome probably induced by herbal medicine. Ann Dermatol. 2018;30(4):481–3.
Oluwo AO, Folakemi Olutoyin FO, Mabogunje CA. Oral manifestations of herbal medicine induced Steven Johnson Syndrome in 3 Nigerian paediatric patients: case report. Pan Afr Med J. 2020;4:1–8.
Ye Z, Li C, Zhang H, Zhang C, Lu X. Mapping of susceptible variants for cold medicine-related Stevens–Johnson syndrome by whole-genome resequencing. Clin. 2022;15:1979–90.
Meyerle JH. Evaluation of vesicular-bullous rash [Internet]. 2019. Available from: https://bestpractice.bmj.com/topics/en-us/775
Wolf R, Davidovici BB, Parish JL, Parish LC, eds. Emergency dermatology. 1st ed. New York: Cambridge University Press; 2010.
Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol. 2002;8:1.
Gupta LK, Martin AM, Agarwal N, Souza PD, Das S, Kumar R, et al. Guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. IJDVL. 2016;82:603–25.
Surowiecka A, Bara´nska-Rybak W, Struzyna J. Multidisciplinary treatment in toxic epidermal necrolysis. Int J Environ Res Public Heal. 2023;20:2217.
Shanbhag SS, Chodosh J, Fathy C, Goverman J, Mitchell C, Saeed HN. Multidisciplinary care in Stevens-Johnson syndrome. Ther Adv Chronic Dis. 2020;11:1–17.
Ingen‑Housz‑Oro S, Schmidt V, Ameri MM, Abe R, Brassard A, Mostaghimi A, et al. Post‑acute phase and sequelae management of epidermal necrolysis: An international, multidisciplinary DELPHI‑based consensus. Orphanet J Rare Dis. 2023;18:1–10.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
